European Journal of Cancer
Volume 41, Issue 11 , Pages 1503-1514 , July 2005

The emerging family of hepatoblastoma tumours: From ontogenesis to oncogenesis

Received 6 September 2004 ,Revised 13 December 2004 ,Accepted 25 February 2005.

References 

  1. Perilongo G, Plaschkes J, Zimmermann A. Hepatic tumours. In: 2nd ed..  Souhami RL,  Tannock I,  Hohenberger P,  Horiot JC editor. Oxford textbook of oncology. vol. 2:Oxford: Oxford University Press; 2002;p. 2657–2668
  2. Darbari A, Sabin KM, Shapiro CN, et al. Epidemiology of primary hepatic malignancies in US children. Hepatology. 2003;38:560–566
  3. Weinberg AG, Finegold MJ. Primary hepatic tumours of childhood. Hum Pathol. 1983;14:512–537
  4. Stocker JT. Hepatoblastoma. Semin Diagn Pathol. 1994;11:136–143
  5. Rowland JM. Hepatoblastoma: assessment of criteria for histologic classification. Med Pediatr Oncol. 2002;39:478–483
  6. Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer. 1989;64:1082–1095
  7. Lack EE, Neave C, Vawter GF. Hepatoblastoma. A clinical and pathologic study of 54 cases. Am J Surg Pathol. 1982;6:693–705
  8. Brotto M, Finegold MJ. Distinct patterns of p27/KIP1 gene expression in hepatoblastoma and prognostic implications with correlation before and after chemotherapy. Hum Pathol. 2002;33:198–205
  9. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of paediatric hepatoblastoma: a report from the Children’s Cancer Group and the Paediatric Oncology Group. J Clin Oncol. 2000;18:2665–2675
  10. Haas JE, Feusner JH, Finegold MJ. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer. 2001;92:3130–3134
  11. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumour-new definitions with prognostic significance: a report from the National Wilms Tumour Study Group. Am J Surg Pathol. 1996;20:909–920
  12. Giangaspero F, Rigobello L, Badiali M, et al. Large-cell medulloblastoma. A distinct variant with highly aggressive behavior. Am J Surg Pathol. 1992;16:687–693
  13. Tornoczky T, Kalman E, Kajtar PG, et al. Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior. Cancer. 2004;100:390–397
  14. Ruck P, Xiao JC, Pietsch T, et al. Hepatic stem-like cells in hepatoblastoma: expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV-1 and OV-6. Histopathology. 1997;31:324–329
  15. Badve S, Logdberg L, Lal A, et al. Small cells in hepatoblastoma lack “oval” cell phenotype. Mod Pathol. 2003;16:930–936
  16. Stocker JT, Conran RM, Selby DM. Tumours and pseudotumours of the liver. In:  Stocker JT,  Askin FB editor. Pathology of solid tumours in children. London: Chapman & Hall Medical; 1998;p. 97–99
  17. Conran RM, Hitchcock CL, Waclawiw MA, et al. Hepatoblastoma: the prognostic significance of histologic type. Pediatr Pathol. 1992;12:167–183
  18. Von Schweinitz D, Wischmeyer P, Leuschner I, et al. Clinico-pathlogical criteria with prognostic relevance in hepatoblastoma. Eur J Cancer. 1994;30A:1052–1058
  19. Von Schweinitz D, Hecker H, Schmidt-von Arndt G, et al. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer. 1997;74:593–599
  20. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma – results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1. Eur J Cancer. 2000;36:1418–1425
  21. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Paediatric Liver Tumour Study HB 94. Cancer. 2002;95:172–182
  22. Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology – SIOPEL 2. Eur J Cancer. 2004;40:411–421
  23. Suita S, Tajiri T, Takamatsu H, et al. Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen – a report from the study group for paediatric solid malignant tumours in the Kyushu area. J Pediatr Surg. 2004;39:195–198
  24. Prokurat A, Kluge P, Kosciesza A, et al. Transitional liver cell tumours (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumours expressing beta-catenin. Med Pediatr Oncol. 2002;39:510–518
  25. Yamada S, Ohira M, Horie H, et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene. 2004;23:5901–5911
  26. Albrecht S, Hartmann W, Houshdaran F, et al. Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma. Int J Cancer. 2004;111:627–632
  27. Nagai H, Naka T, Terada Y, et al. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet. 2003;48:65–69
  28. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483–1487
  29. Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol. 2002;39:530–535
  30. Park WS, Oh RR, Park JY, et al. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol. 2001;193:483–490
  31. Takayasu H, Horie H, Hiyama E, et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res. 2001;7:901–908
  32. Shang XZ, Zhu H, Lin K, et al. Stabilized beta-catenin promotes hepatocyte proliferation and inhibits TNFalpha-induced apoptosis. Lab Invest. 2004;84:332–341
  33. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002;21:4863–4871
  34. Thomas D, Pritchard J, Davidson R, et al. Familial hepatoblastoma and APC gene mutations: renewed call for molecular research. Eur J Cancer. 2003;39:2200–2204
  35. Wirths O, Waha A, Weggen S, et al. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms’ tumours. Lab Invest. 2003;83:429–434
  36. Saxena R, Leake JL, Shafford EA, et al. Chemotherapy effects on hepatoblastoma. A histological study. Am J Surg Pathol. 1993;17:1266–1271
  37. Heifetz SA, French M, Correa M, et al. Hepatoblastoma: the Indiana experience with preoperative chemotherapy for inoperable tumours: clinicopathological considerations. Pediatr Pathol Lab Med. 1997;17:857–874
  38. Heerema A, Finegold M. ACTH-producing stromal–epithelial tumours of the liver. Lab Invest. 2004;84:270;[Abstract]
  39. Zimmermann A. Hepatoblastoma with cholangioblastic features (‘cholangioblastic hepatoblastoma’) and other liver tumours with a bimodal differentiation in young patients. Med Pediatr Oncol. 2002;39:487–491
  40. Libbrecht L, Desmet V, Roskams T. Stages of normal and aberrant intrahepatic bile duct development in a mixed hepatoblastoma. Histopathology. 2003;42:618–620
  41. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology. 2004;39:1739–1745
  42. Allison RM, Willis RA. An ossifying embryonic mixed tumour of an infant’s liver. J Pathol Bacteriol. 1956;72:155–159
  43. Gornicka B, Ziarkiewicz-Wroblewska B, Michalowicz B, et al. Immature hepatic tumour of bimodal differentiation in a young adult patient: a novel lesion expressing beta-catenin and mimicking a distinct phase of hepatogenesis. J Hepatol. 2001;34:955–961
  44. Zaret KS. Hepatocyte differentiation: from the endoderm and beyond. Curr Opin Genet Dev. 2000;11:568–574
  45. Zaret KS. Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet. 2000;3:499–512
  46. Duncan SA. Mechanisms controlling early development of the liver. Mech Dev. 2003;120:19–33
  47. Costa RH, Kalinichenko VV, Holterman AX, et al. Transcription factors in liver development, differentiation, and regeneration. Hepatology. 2003;38:1331–1347
  48. Tanimizu N, Miyajima A. Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J Cell Sci. 2004;117:3165–3174
  49. Sosa-Pineda B, Wigle JT, Oliver G. Hepatocyte migration during liver development requires Prox1. Nat Genet. 2002;25:254–255
  50. Kolterud A, Wandzioch E, Carlsson L. Lhx2 is expressed in the septum transversum mesenchyme that becomes an integral part of the liver and the formation of these cells is independent of functional Lhx2. Gene Expr Patterns. 2004;4:521–528
  51. Chagraoui J, Lepage-Noll A, Anjo A, et al. Foetal liver stroma consists of cells in epithelial-to-mesenchymal transition. Blood. 2003;101:2973–2982
  52. Watt AJ, Garrison WD, Duncan SA. HNF4: a central regulator of hepatocyte differentiation and function. Hepatology. 2003;37:1249–1253
  53. Crawford JM. Development of the intrahepatic biliary tree. Semin Liver Dis. 2002;22:213–226
  54. Clotman F, Lannoy VJ, Reber M, et al. The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development. 2002;129:1819–1828
  55. Coffinier C, Gresh L, Fiette L, et al. Bile system morphogenesis defects and liver dysfunction upon targeted deletion of HNF1b. Development. 2002;129:1829–1838
  56. McCright B, Lozier J, Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 hapolinsufficiency. Development. 2002;129:1075–1082
  57. Ong AC, Wheatley DN. Polycystic kidney disease – the ciliary connection. Lancet. 2003;361:774–776
  58. Masyuk TV, Huang BQ, Ward CJ, et al. Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology. 2003;125:1303–1310
  59. Harris PC, Rossetti S. Molecular genetics of autosomal recessive polycystic kidney disease. Mol Genet Metab. 2004;81:75–85
  60. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer. 1999;86:364–372
  61. Peuchmaur M, d’Amore ESG, Hata J, et al. Revision of the International Neuroblastoma Pathology Classification. Confirmation of favorableand unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003;98:2274–2281
  62. Beckwith JB, Zuppan CE, Browning NG, et al. Histological analysis of aggressiveness and responsiveness in Wilms’ tumour. Med Pediatr Oncol. 1996;27:422–428
  63. Boccon-Gibod LA. Pathological evaluation of renal tumours in children: International Society of Paediatric Oncology approach. Pediatr Dev Pathol. 1998;1:243–248
  64. Vujanic GM, Sandstedt B, Harms D, et al. On behalf of the SIOP Nephroblastoma Scientific Committee Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumours of childhood. Med Pediatr Oncol. 2002;38:79–82

PII: S0959-8049(05)00349-7

doi: 10.1016/j.ejca.2005.02.035

European Journal of Cancer
Volume 41, Issue 11 , Pages 1503-1514 , July 2005

Article Tools

* Image Usage & Resolution